Market Overview

UPDATE: Morgan Stanley Downgrades Catamaran on Balanced Risk-Reward

UPDATE: Morgan Stanley Reiterates Equal-Weight Rating on Catamaran Corp Following Salveo Acquisition
Catamaran To acquire Salveo Specialty Pharmacy For $260M In Cash

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser downgraded the rating on Catamaran Corp. (NASDAQ: CTRX) from Overweight to Equal-Weight, and removed the $60.00 price target.

In the report, Morgan Stanley noted, “A maturing growth profile and premium to the group likely cap CTRX's multiple expansion opportunity. While we think mgmt will execute and grow EPS via M&A and CI, with topline CAGR moderating to 25% thru ‘15 vs. 75% from '08-‘13E and given evolving PBM dynamics, we view risk-reward as balanced.”

Catamaran Corp. closed on Friday at $49.52.

Latest Ratings for CTRX

Feb 2015Deutsche BankMaintainsHold
Feb 2015Leerink SwannMaintainsOutperform
Feb 2015BarclaysMaintainsEqualweight

View More Analyst Ratings for CTRX
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Downgrades Analyst Ratings


Related Articles (CTRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→